We monitor the B cell and antibody responses to infection by HIV-1 and SARS-CoV-2 and we identify immunological and virological factors associated with the development of protective antibodies. The underlying immunological reasons that are responsible for differences in the immune response to infection by adults and children are examined.
Molecular, structural and modeling approaches are employed to design immunogens capable of eliciting neutralizing, protective antibodies against HIV-1, SARS-CoV-2 and Malaria. High-throughput assays platforms are employed to analyze and compare the complex immune responses elicited by each novel immunogen.